These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


420 related items for PubMed ID: 21502956

  • 1. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.
    Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Möllgård L, Derolf AR, Stockelberg D, Tidefelt U, Wahlin A, Wennström L, Höglund M, Juliusson G.
    Leukemia; 2011 Jul; 25(7):1128-34. PubMed ID: 21502956
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group.
    Bally C, Fadlallah J, Leverger G, Bertrand Y, Robert A, Baruchel A, Guerci A, Recher C, Raffoux E, Thomas X, Leblanc T, Idres N, Cassinat B, Vey N, Chomienne C, Dombret H, Sanz M, Fenaux P, Adès L.
    J Clin Oncol; 2012 May 10; 30(14):1641-6. PubMed ID: 22473162
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution.
    Pollicardo N, O'Brien S, Estey EH, al-Bitar M, Pierce S, Keating M, Kantarjian HM.
    Leukemia; 1996 Jan 10; 10(1):27-31. PubMed ID: 8558933
    [Abstract] [Full Text] [Related]

  • 10. Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials.
    Micol JB, Raffoux E, Boissel N, Lengliné E, Canet E, Daniel MT, Labarthe Ad, Maarek O, Cassinat B, Adès L, Baruchel A, Degos L, Azoulay E, Dombret H.
    Eur J Cancer; 2014 Apr 10; 50(6):1159-68. PubMed ID: 24440088
    [Abstract] [Full Text] [Related]

  • 11. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
    Dai CW, Zhang GS, Shen JK, Zheng WL, Pei MF, Xu YX, Cao YX, Yi Y, Yang JJ, Peng HL, Zhong HY, Li RJ.
    Acta Haematol; 2009 Apr 10; 121(1):1-8. PubMed ID: 19246888
    [Abstract] [Full Text] [Related]

  • 12. Morbidity and costs of remission induction therapy with all-trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia.
    Eardley AM, Heller G, Warrell RP.
    Leukemia; 1994 Jun 10; 8(6):934-9. PubMed ID: 8207987
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan.
    Ohno R, Ohnishi K, Takeshita A, Tanimoto M, Murakami H, Kanamaru A, Asou N, Kobayashi T, Kuriyama K, Ohmoto E.
    Leukemia; 1994 Jun 10; 8 Suppl 3():S64-9. PubMed ID: 7808028
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia.
    Kim DY, Lee JH, Lee JH, Kim SD, Lim SN, Choi Y, Lee YS, Kang YA, Seol M, Jeon M, Kim JY, Lee KH, Lee YJ, Lee KH.
    Leuk Res; 2011 Feb 10; 35(2):152-8. PubMed ID: 20554322
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 21.